Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantac 75 launches planned by Warner-Lambert for Canada, Australia, European countries.

This article was originally published in The Tan Sheet

Executive Summary

ZANTAC 75 "ON TRACK" FOR CANADIAN LAUNCH, Warner-Lambert Chairman and CEO Melvin Goodes told securities analysts in New York City April 17. The launch would make Zantac 75 the second nonprescription H2 blocker in Canada; J&J/Merck introduced Pepcid AC there early last summer ("The Tan Sheet" July 1, 1996, In Brief). Warner-Lambert appears undaunted by J&J/Merck's significant jump on the market in Canada. SmithKline Beecham, however, recently terminated Canadian switch efforts for Tagamet HB, citing the "competitive disadvantage" that would result from trailing so far behind Pepcid AC ("The Tan Sheet" Jan. 27, In Brief).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel